RÉSUMÉ
We aimed to evaluate the influence of exogenetic insulin on bone mineral density [BMD] in Type 2 Diabetes Mellitus [T[2]DM]. Group A included 120 cases of middle-aged male patients with type 2 diabetes mellitus were administrated exogenetic insulin [40 cases in Group A[1]: for less than 1 year; 40 cases in Group A[2]:for 1 to 3 years; 40cases in Group A[3]: for 3 to 5 years], and another 120 cases [Group B] of middle-aged male patients with type 2 diabetes mellitus were administrated insulin secretagogues. The measurements of BMD of lumbar vertebra [L2-4], collum femoris and total body were conducted with dual-energy X-raya bsorptiometry, followed by the determination of glycosylated hemoglobin, plasma insulin concentration [fasting and postprandial], and fasting C-peptide. Our results revealed that there was no statistical difference of BMD [P>0.05] between patients in Group A[1]or A[3]andpatients in Group B [B[1], B[2] or B[3]], while the BMD in Group A[2] increased significantly [P<0.05]. And the fracture risk in Group A[3] increased significantly [P<0.05] compared with Group B [B[1], B[2] or B[3]], Taken together, exogenetic insulin significantly increased BMD and fracture risk of middle-aged male patients with type 2 diabetes mellitus